Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Alzheimer's Disease

  Free Subscription


Articles published in Brain

Retrieve available abstracts of 88 articles:
HTML format
Text format



Single Articles


    August 2017
  1. DERRY PJ, Kent TA
    Correlating quantitative susceptibility mapping with cognitive decline in Alzheimer's disease.
    Brain. 2017;140:2069-2072.
    PubMed     Text format    


  2. KIM H, Yoo J, Shin J, Chang Y, et al
    Modelling APOE varepsilon3/4 allele-associated sporadic Alzheimer's disease in an induced neuron.
    Brain. 2017;140:2193-2209.
    PubMed     Text format     Abstract available


  3. AYTON S, Fazlollahi A, Bourgeat P, Raniga P, et al
    Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline.
    Brain. 2017;140:2112-2119.
    PubMed     Text format     Abstract available


    July 2017
  4. YEW B, Nation DA
    Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
    Brain. 2017;140:1987-2001.
    PubMed     Text format     Abstract available


    June 2017
  5. GEORGE C, Gontier G, Lacube P, Francois JC, et al
    The Alzheimer's disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons.
    Brain. 2017 Jun 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  6. PARBO P, Ismail R, Hansen KV, Amidi A, et al
    Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease.
    Brain. 2017 May 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. DANSOKHO C, Aucouturier P, Dorothee G
    Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology.
    Brain. 2017 May 12. doi: 10.1093.
    PubMed     Text format    


  8. ALVES S, Churlaud G, Klatzmann D, Cartier N, et al
    Reply: Beneficial effect of interleukin-2-based immunomodulation in Alzheimer-like pathology.
    Brain. 2017 May 12. doi: 10.1093.
    PubMed     Text format    


    April 2017
  9. HARDY J, De Strooper B
    Alzheimer's disease: where next for anti-amyloid therapies?
    Brain. 2017;140:853-855.
    PubMed     Text format    


  10. CARAVAGGIO F, Graff-Guerrero A
    Is antipsychotic sensitivity in Alzheimer's disease secondary to abnormal blood-brain barrier integrity?
    Brain. 2017;140:865-867.
    PubMed     Text format    


    March 2017
  11. YU M, Engels MM, Hillebrand A, van Straaten EC, et al
    Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study.
    Brain. 2017 Mar 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. ROBERTS BR, Lind M, Wagen AZ, Rembach A, et al
    Biochemically-defined pools of amyloid-beta in sporadic Alzheimer's disease: correlation with amyloid PET.
    Brain. 2017 Mar 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. COULTHARD E, Knight M
    Refining Alzheimer's disease diagnosis with MRI.
    Brain. 2017;140:524-526.
    PubMed     Text format    


    February 2017
  14. BANERJEE G, Kim HJ, Fox Z, Jager HR, et al
    MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden.
    Brain. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. REEVES S, McLachlan E, Bertrand J, Antonio FD, et al
    Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Brain. 2017 Feb 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. HUSAIN M
    Alzheimer's disease: time to focus on the brain, not just molecules.
    Brain. 2017;140.
    PubMed     Text format    


    January 2017
  17. PASSAMONTI L, Vazquez Rodriguez P, Hong YT, Allinson KS, et al
    18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
    Brain. 2017 Jan 24. pii: aww340. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. FAN Z, Brooks DJ, Okello A, Edison P, et al
    An early and late peak in microglial activation in Alzheimer's disease trajectory.
    Brain. 2017 Jan 24. pii: aww349. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. HAYES JP, Logue MW, Sadeh N, Spielberg JM, et al
    Mild traumatic brain injury is associated with reduced cortical thickness in those at risk for Alzheimer's disease.
    Brain. 2017 Jan 11. pii: aww344. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. PONTECORVO MJ, Devous MD Sr, Navitsky M, Lu M, et al
    Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Brain. 2017 Jan 11. pii: aww334. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. CAPSONI S, Malerba F, Carucci NM, Rizzi C, et al
    The chemokine CXCL12 mediates the anti-amyloidogenic action of painless human nerve growth factor.
    Brain. 2017;140.
    PubMed     Text format     Abstract available


  22. AHMED RM, Landin-Romero R, Collet TH, van der Klaauw AA, et al
    Energy expenditure in frontotemporal dementia: a behavioural and imaging study.
    Brain. 2017;140.
    PubMed     Text format     Abstract available


    December 2016
  23. ALVES S, Churlaud G, Audrain M, Michaelsen-Preusse K, et al
    Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice.
    Brain. 2016 Dec 20. pii: aww330. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. DONG A, Toledo JB, Honnorat N, Doshi J, et al
    Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.
    Brain. 2016 Dec 20. pii: aww319. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2016
  25. ROGAEVA E, Schmitt-Ulms G
    Does BDNF Val66Met contribute to preclinical Alzheimer's disease?
    Brain. 2016;139.
    PubMed     Text format    


    September 2016
  26. JAMES BD, Wilson RS, Boyle PA, Trojanowski JQ, et al
    TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.
    Brain. 2016.
    PubMed     Text format     Abstract available


  27. O'SULLIVAN MJ, Vann SD
    Amyloid imaging and Alzheimer's disease: the unsolved cases.
    Brain. 2016;139.
    PubMed     Text format    


  28. COHEN AD
    Distinct pathways for cognitive decline in the presence of Alzheimer's disease pathology or cerebrovascular disease.
    Brain. 2016;139.
    PubMed     Text format    


    August 2016
  29. TIWARI SS, Mizuno K, Ghosh A, Aziz W, et al
    Alzheimer-related decrease in CYFIP2 links amyloid production to tau hyperphosphorylation and memory loss.
    Brain. 2016.
    PubMed     Text format     Abstract available


  30. LIM YY, Hassenstab J, Cruchaga C, Goate A, et al
    BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  31. HANSSON O, Gouras G
    Brain activity and Alzheimer's disease: a complex relationship.
    Brain. 2016;139.
    PubMed     Text format    


    July 2016
  32. LEWCZUK P, Kornhuber J
    Do we still need positron emission tomography for early Alzheimer's disease diagnosis?
    Brain. 2016.
    PubMed     Text format    


  33. PALMQVIST S, Mattsson N, Hansson O
    Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?
    Brain. 2016.
    PubMed     Text format    


    June 2016
  34. CHETELAT G, Ossenkoppele R, Villemagne VL, Perrotin A, et al
    Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  35. GORDON BA, Friedrichsen K, Brier M, Blazey T, et al
    The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.
    Brain. 2016.
    PubMed     Text format     Abstract available


    May 2016
  36. WOODLING NS, Colas D, Wang Q, Minhas P, et al
    Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice.
    Brain. 2016.
    PubMed     Text format     Abstract available


  37. OH H, Madison C, Baker S, Rabinovici G, et al
    Dynamic relationships between age, amyloid-beta deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  38. SARAZIN M, Lagarde J, Bottlaender M
    Distinct tau PET imaging patterns in typical and atypical Alzheimer's disease.
    Brain. 2016;139.
    PubMed     Text format    


  39. THAL DR, Vandenberghe R
    Monitoring the progression of Alzheimer's disease with tau-PET.
    Brain. 2016;139.
    PubMed     Text format    


  40. SCHMAHMANN JD
    Cerebellum in Alzheimer's disease and frontotemporal dementia: not a silent bystander.
    Brain. 2016;139.
    PubMed     Text format    


    April 2016
  41. AGGLETON JP, Pralus A, Nelson AJ, Hornberger M, et al
    Thalamic pathology and memory loss in early Alzheimer's disease: moving the focus from the medial temporal lobe to Papez circuit.
    Brain. 2016.
    PubMed     Text format     Abstract available


  42. RABINOVICI GD
    Amyloid biomarkers: pushing the limits of early detection.
    Brain. 2016;139.
    PubMed     Text format    


  43. HARPER L, Fumagalli GG, Barkhof F, Scheltens P, et al
    MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases.
    Brain. 2016;139.
    PubMed     Text format     Abstract available


  44. HABES M, Erus G, Toledo JB, Zhang T, et al
    White matter hyperintensities and imaging patterns of brain ageing in the general population.
    Brain. 2016;139.
    PubMed     Text format     Abstract available


    March 2016
  45. HAMELIN L, Lagarde J, Dorothee G, Leroy C, et al
    Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging.
    Brain. 2016.
    PubMed     Text format     Abstract available


  46. OSSENKOPPELE R, Schonhaut DR, Scholl M, Lockhart SN, et al
    Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  47. PALMQVIST S, Mattsson N, Hansson O
    Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography.
    Brain. 2016.
    PubMed     Text format     Abstract available


  48. SCHWARZ AJ, Yu P, Miller BB, Shcherbinin S, et al
    Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Brain. 2016.
    PubMed     Text format     Abstract available


  49. DURAN-ANIOTZ C, Cornejo VH, Hetz C
    Targeting endoplasmic reticulum acetylation to restore proteostasis in Alzheimer's disease.
    Brain. 2016;139.
    PubMed     Text format    


  50. SCHOTT JM, Fox NC
    Inflammatory changes in very early Alzheimer's disease: friend, foe, or don't know?
    Brain. 2016;139.
    PubMed     Text format    


  51. DUZEL E, van Praag H, Sendtner M
    Can physical exercise in old age improve memory and hippocampal function?
    Brain. 2016;139.
    PubMed     Text format     Abstract available


    February 2016
  52. SPANGENBERG EE, Lee RJ, Najafi AR, Rice RA, et al
    Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-beta pathology.
    Brain. 2016.
    PubMed     Text format     Abstract available


  53. GUO CC, Tan R, Hodges JR, Hu X, et al
    Network-selective vulnerability of the human cerebellum to Alzheimer's disease and frontotemporal dementia.
    Brain. 2016.
    PubMed     Text format     Abstract available


  54. DANSOKHO C, Ait Ahmed D, Aid S, Toly-Ndour C, et al
    Regulatory T cells delay disease progression in Alzheimer-like pathology.
    Brain. 2016.
    PubMed     Text format     Abstract available


    January 2016
  55. RODRIGUEZ-VIEITEZ E, Saint-Aubert L, Carter SF, Almkvist O, et al
    Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  56. ZHU QB, Unmehopa U, Bossers K, Hu YT, et al
    MicroRNA-132 and early growth response-1 in nucleus basalis of Meynert during the course of Alzheimer's disease.
    Brain. 2016.
    PubMed     Text format     Abstract available


  57. PENG Y, Kim MJ, Hullinger R, O'Riordan KJ, et al
    Improved proteostasis in the secretory pathway rescues Alzheimer's disease in the mouse.
    Brain. 2016.
    PubMed     Text format     Abstract available


  58. OLMOS-ALONSO A, Schetters ST, Sri S, Askew K, et al
    Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology.
    Brain. 2016.
    PubMed     Text format     Abstract available


  59. JAGUST W
    Is amyloid-beta harmful to the brain? Insights from human imaging studies.
    Brain. 2016;139.
    PubMed     Text format     Abstract available


    December 2015
  60. HAAS LT, Salazar SV, Kostylev MA, Um JW, et al
    Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  61. KIMBROUGH IF, Robel S, Roberson ED, Sontheimer H, et al
    Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


  62. SORG C, Grothe MJ
    The complex link between amyloid and neuronal dysfunction in Alzheimer's disease.
    Brain. 2015;138.
    PubMed     Text format    


    November 2015
  63. JONES DT, Knopman DS, Gunter JL, Graff-Radford J, et al
    Cascading network failure across the Alzheimer's disease spectrum.
    Brain. 2015.
    PubMed     Text format     Abstract available


  64. RYAN NS, Rossor MN, Fox NC
    Alzheimer's disease in the 100 years since Alzheimer's death.
    Brain. 2015.
    PubMed     Text format    


  65. FLETCHER PD, Downey LE, Golden HL, Clark CN, et al
    Pain and temperature processing in dementia: a clinical and neuroanatomical analysis.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


    October 2015
  66. FAN Z, Okello AA, Brooks DJ, Edison P, et al
    Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  67. ESCOTT-PRICE V, Sims R, Bannister C, Harold D, et al
    Common polygenic variation enhances risk prediction for Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  68. MAYA Y, Okumura Y, Kobayashi R, Onishi T, et al
    Preclinical properties and human in vivo assessment of 123I-ABC577 as a novel SPECT agent for imaging amyloid-beta.
    Brain. 2015.
    PubMed     Text format     Abstract available


  69. KULLMANN DM
    Editorial.
    Brain. 2015;138.
    PubMed     Text format    


  70. TAN RH, Kril JJ, Fatima M, McGeachie A, et al
    TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


    September 2015
  71. PORTELIUS E, Zetterberg H, Skillback T, Tornqvist U, et al
    Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


    August 2015
  72. BRAAK H, Del Tredici K
    The preclinical phase of the pathological process underlying sporadic Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  73. FRINGS L, Hellwig S, Spehl TS, Bormann T, et al
    Asymmetries of amyloid-beta burden and neuronal dysfunction are positively correlated in Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  74. RAMANAN VK, Risacher SL, Nho K, Kim S, et al
    GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP.
    Brain. 2015.
    PubMed     Text format     Abstract available


  75. CLARK CN, Warren JD
    Music, memory and mechanisms in Alzheimer's disease.
    Brain. 2015;138.
    PubMed     Text format    


    July 2015
  76. TOLEDO JB, Zetterberg H, van Harten AC, Glodzik L, et al
    Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
    Brain. 2015.
    PubMed     Text format     Abstract available


  77. DJELTI F, Braudeau J, Hudry E, Dhenain M, et al
    CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  78. OSSENKOPPELE R, Pijnenburg YA, Perry DC, Cohn-Sheehy BI, et al
    The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.
    Brain. 2015.
    PubMed     Text format     Abstract available


  79. ANTONIADES CA, Kennard C
    Oculomotor abnormalities in posterior cortical atrophy: are they different from those in Alzheimer's disease after all?
    Brain. 2015;138.
    PubMed     Text format    


  80. CUMMINGS DM, Liu W, Portelius E, Bayram S, et al
    First effects of rising amyloid-beta in transgenic mouse brain: synaptic transmission and gene expression.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


  81. SHAKESPEARE TJ, Kaski D, Yong KX, Paterson RW, et al
    Abnormalities of fixation, saccade and pursuit in posterior cortical atrophy.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


    June 2015
  82. KORONYO Y, Salumbides BC, Sheyn J, Pelissier L, et al
    Therapeutic effects of glatiramer acetate and grafted CD115+ monocytes in a mouse model of Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  83. JACOBSEN JH, Stelzer J, Fritz TH, Chetelat G, et al
    Why musical memory can be preserved in advanced Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  84. DICKSON DW, Murray ME
    Intraneuronal amyloid-beta accumulation in basal forebrain cholinergic neurons: a marker of vulnerability, yet inversely related to neurodegeneration.
    Brain. 2015;138.
    PubMed     Text format    


    May 2015
  85. KROHN M, Bracke A, Avchalumov Y, Schumacher T, et al
    Accumulation of murine amyloid-beta mimics early Alzheimer's disease.
    Brain. 2015.
    PubMed     Text format     Abstract available


  86. WANG DB, Kinoshita Y, Kinoshita C, Uo T, et al
    Loss of endophilin-B1 exacerbates Alzheimer's disease pathology.
    Brain. 2015.
    PubMed     Text format     Abstract available


  87. VILLENEUVE S, Rabinovici GD, Cohn-Sheehy BI, Madison C, et al
    Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.
    Brain. 2015.
    PubMed     Text format     Abstract available


  88. SHULTZ SR, Wright DK, Zheng P, Stuchbery R, et al
    Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury.
    Brain. 2015;138.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: